rHuPH20

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Multiple MyelomaMelanomaAdultHIV InfectionsNeuropathy

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

1

Empliciti

Bristol-Myers Squibb

Phase 3

452

Belamaf

GSK

Phase 3

393

TALVEY

Johnson & Johnson

Phase 3

244

Sarclisa

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

425

Biaxin

AbbVie

Phase 3

156

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

297

Vepesid

AAvyxa

Phase 3

178

Mozobil

GGenzyme, a Sanofi Company

Phase 3

159

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

1010

Mezigdomide

Bristol-Myers Squibb

Phase 3

11Show 28 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Intravenous3 trials

Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03538626·33 enrolled

Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects

Completed·AstraZeneca·Phase 1·NCT04920370·97 enrolled

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

Completed·GSK·Phase 1·NCT05291520·24 enrolled

Adult2 trials

A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants

Recruiting·GSK·Phase 1·NCT05418868·214 enrolled

Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers

Completed·AstraZeneca·Phase 1·NCT05396742·49 enrolled

HIV Infections2 trials

A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled Randomized, Single Ascending Dose and Multiple Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Parenterally Administered VH4524184 in Healthy Adults

Recruiting·GSK·Phase 1·NCT06310551·372 enrolled

A Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion With rHuPH20, in Combination With CAB LA to Standard of Care in Virologically Suppressed Adults Living With HIV

Active, not recruiting·GSK·Phase 2·NCT05996471·185 enrolled

Nivolumab1 trial

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Completed·Bristol-Myers Squibb·Phase 1·NCT04112498·24 enrolled

Immunotherapy1 trial

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Terminated·Bristol-Myers Squibb·Phase 1/2·NCT03446040·92 enrolled

11 more indications

Daratumumab1 trial

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants

Completed·Johnson & Johnson·Phase 1·NCT03320707·66 enrolled

Non-Small Cell Lung Cancer1 trial

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed·Roche·Phase 3·NCT03735121·438 enrolled

Melanoma1 trial

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

Active, not recruiting·Bristol-Myers Squibb·Phase 3·NCT05625399·579 enrolled

MPA1 trial

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

Completed·HHalozyme Therapeutics·Phase 1·NCT00862849·22 enrolled

Monotherapy1 trial

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

Completed·Bristol-Myers Squibb·Phase 1/2·NCT03656718·139 enrolled

Multiple Sclerosis1 trial

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

Completed·Roche·Phase 1·NCT03972306·134 enrolled

Experimental1 trial

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

Completed·Bristol-Myers Squibb·Phase 1/2·NCT02754141·235 enrolled

Allergic Contact Dermatitis1 trial

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

Completed·HHalozyme Therapeutics·Phase 2·NCT00928447·22 enrolled

Neuropathy1 trial

HyQvia in Multifocal Motor Neuropathy

Unknown status·UUMC Utrecht·N/A·NCT02885259·20 enrolled

Multiple Myeloma1 trial

A Randomized, Open-label, Phase 1b, Crossover Study to Evaluate the Pharmacokinetics and Safety of a Subcutaneous Belantamab (BCMAb) Formulation With rHuPH20 Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care

Not yet recruiting·GSK·Phase 1·NCT07742527·22 enrolled

Unspecified2 trials

Pharmacokinetic, Safety and Tolerability Study of SC Administered Bisphosphonate With rHuPH20 vs Bisphosphonate Alone

Completed·HHalozyme Therapeutics·Phase 1·NCT00807963·31 enrolled

Dose-Ranging, Pharmacokinetic (PK), Glucodynamic (GD), Safety and Tolerability Study of Subcutaneously (SC) Administered Humulin R and Humalog With or Without rHuPH20

Completed·HHalozyme Therapeutics·Phase 1·NCT00803972·42 enrolled

Details

Drug Info

Related News